Randomized, prospective, placebo‐controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis

Objective Endothelin is implicated as a participatory pathway in systemic sclerosis (SSc). We tested this hypothesis in a 12‐month trial of bosentan, a nonselective endothelin receptor antagonist, as a therapy for SSc‐related interstitial lung disease (ILD). Method Patients with SSc and significant...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 2010-07, Vol.62 (7), p.2101-2108
Main Authors: Seibold, J. R., Denton, C. P., Furst, D. E., Guillevin, L., Rubin, L. J., Wells, A., Matucci Cerinic, M., Riemekasten, G., Emery, P., Chadha‐Boreham, H., Charef, P., Roux, S., Black, C. M.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Bosentan
Comorbidity
Diseases of the osteoarticular system
Double-Blind Method
Exercise Test
Female
Humans
Lung Diseases, Interstitial - drug therapy
Lung Diseases, Interstitial - epidemiology
Lung Diseases, Interstitial - physiopathology
Male
Medical sciences
Middle Aged
Pneumology
Prospective Studies
Quality of Life
Respiratory Function Tests
Respiratory system : syndromes and miscellaneous diseases
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Scleroderma, Systemic - drug therapy
Scleroderma, Systemic - epidemiology
Scleroderma, Systemic - physiopathology
Sulfonamides - therapeutic use
Survival Rate
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Endothelin is implicated as a participatory pathway in systemic sclerosis (SSc). We tested this hypothesis in a 12‐month trial of bosentan, a nonselective endothelin receptor antagonist, as a therapy for SSc‐related interstitial lung disease (ILD). Method Patients with SSc and significant ILD were recruited to this prospective, double‐blind, randomized, placebo‐controlled, parallel group study. The inclusion criteria were designed to select a cohort enriched for patients with active and progressive disease. Exclusion factors included significant pulmonary hypertension. Patients with a diffusing capacity for carbon monoxide of
ISSN:0004-3591
1529-0131
DOI:10.1002/art.27466